Teva Pharmaceutical Industries Limited Sees 2014 Profit Drop If Copaxone Competition Launched

Published: Dec 10, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Teva Pharmaceutical Industries , the world's biggest generic drugmaker, forecast a big drop in profit in 2014 if cheap generic competition to its blockbuster multiple sclerosis treatment Copaxone is launched. Israel-based Teva on Tuesday provided two sets of forecasts for next year - one assuming the launch of at least two generic competitors to Copaxone in the United States on June 1, 2014, and the other assuming no U.S. generic competition in 2014. Assuming Copaxone does face competition, Teva estimates it will earn $4.20 to $4.50 a share on an adjusted basis on revenue of $19.3 billion to $20.3 billion.

Help employers find you! Check out all the jobs and post your resume.

Back to news